


# Supplementary Table S1

| Gene  | Forward Sequence (5'-3') | Reverse Sequence (5'-3') | Species |
|-------|--------------------------|--------------------------|---------|
| IDH2  | CCGTGGTGTTCAGGAAGT       | GAAGGTGTGCGTGGAGAC       | Human   |
| GAPDH | AGGTCGGTGTGAACGGATTG     | GGGGTCGTTGATGGCAACA      | Human   |
| MMP7  | GAGTGAGCTACAGTGGGAACA    | CTATGACGCGGGAGTTTAACAT   | Human   |
| SDC1  | CTGCCGCAAATTGTGGCTAC     | TGAGCCGGAGAAGTTGTCAGA    | Human   |
| SDC2  | TTGACAACAGCTCCATTGAAGAA  | CAGCTCTGGACTCTCTACATCC   | Human   |
| SDC3  | TGGCGCAGTGAGAACTTCG      | CCCCGAGTAGAGGTCATCCAG    | Human   |
| SDC4  | TCCCCACCGAACCCAAGAA      | CCTTGTTGGACACATCCTCAC    | Human   |
| TGF-β | CAATTCCTGGCGATACCTCAG    | GCACAACCTCCGGTGACATCAA   | Human   |
| TNF-α | CCCAGGGACCTCTCTAATCA     | AGCTGCCCCTCAGCTTGAG      | Human   |
| IL-1β | CCCAGGGACCTCTCTAATCA     | AGCTGCCCCTCAGCTTGAG      | Human   |



Supplementary Table 1. Primer sequences used in qPCR analyses.

Supplementary Figure s1




Supplementary Figure 1. Screening of MMP subtypes in HUVECs. HUVECs were transfected with 50pmol of siIDH2 and siCON for 48h. mRNA expressions of (a) IDH2 (b) MMP2 (c) MMP3 (d) MMP7 (e) MMP9 (f) MMP12 (g) MMP14 and (h) ADAM17 were quantified by qPCR. All data are presented as means  $\pm$  SEM of three independent experiments, \*P<0.05, compared with siCON.

Supplementary Figure s2




Supplementary Figure 2. Cell viability and cell proliferation after UTI treatment in HUVECs. (a) After treatment of dose dependent UTI (30, 100, 300 and 1000 U/ml) for 24, 48, 72 and 96 h in HUVECs, cell viability was measured using the ADAM-MC automatic cell counter. (b) HUVECs were transfected with 50pmol of siIDH2 and siCON with or without UTI treatment (1000 U/ml) for 48h. Cell proliferation was measured using the CCK-8 proliferation assay. All data are presented as means  $\pm$  SEM of three independent experiments, \*P<0.05, compared with siCON.

# Supplementary Figure S3



Supplementary Figure 3. Measurement of cell function after UTI treatment in HUVECs. HUVECs were transfected with 50pmol of siIDH2 and siCON with or without UTI treatment (1000 U/ml) for 48h. (a) Cell migration was assessed using the cell scratch assay. (b) Protein levels of PCNA, MMP9 and cleaved caspase 9 were detected by western blotting. β-actin was used as a loading control. Protein levels were quantified by densitometric analysis using Image-J software. All data are presented as means ± SEM of three independent experiments, \*P<0.05, compared with siCON, #P<0.05 compared with the 50pmol siIDH2 treated cells.

Supplementary Figure S4



Supplementary Figure 4. Measurement of cytokines after UTI treatment in HUVECs. HUVECs were transfected with 50pmol of siIDH2 and siCON with or without UTI treatment (1000 U/ml) for 48h. mRNA expressions of (a) TGF-β (b) TNF-α (c) IL-1β and (d) IDH2 were quantified by qPCR. All data are presented as means ±SEM of three independent experiments, \*P<0.05, compared with siCON, #P<0.05 compared with the 50pmol siIDH2 treated cells.